Creative Biolabs is an industry-leading integrated ferroptosis-based cancer therapy development CRO company, providing global pharmaceutical and research workers with innovative oncology research and development solutions across the full cycle. Through a comprehensive service system and top-notch quality standards, we help our clients improve R&D efficiency, reduce R&D risk, and ensure high-quality delivery of research projects.

Introduction to Ferroptosis-based Cancer Therapy

The recently identified ferroptosis is a form of programmed cell death that plays a crucial role in tumor biology and therapy. Different tumors exhibit varying sensitivity to ferroptosis, with emerging evidence suggesting that highly aggressive tumors are particularly susceptible to ferroptosis inducers. This non-apoptotic cell death pathway presents an appealing target for the treatment of "refractory" tumors.

Furthermore, recent findings have linked ferroptosis to T cell-mediated anti-tumor immunity and its impact on the effectiveness of tumor immunotherapy. Therefore, gaining a better understanding of this iron-dependent cell death will be instrumental in identifying novel cancer combination therapy strategies, holding significant biological and clinical implications.

Fig.1 Mechanism Underlying the Occurrence and Regulation of Ferroptosis.¹

Creative Biolabs has independently developed and established several advanced ferroptosis tumor treatment technology platforms, offering a comprehensive range of services including ferroptosis target screening based on small molecules, nanomaterials, and genetic engineering, the construction of ferroptosis-induced tumor models and in vivo and in vitro tumor efficacy verification.

Platforms

As the first CRO to offer ferroptosis-based cancer therapy discovery, Creative Biolabs focuses on the discovery and research of ferroptosis-induced cancer therapy and can provide professional solutions such as target discovery, pharmaceutical research, and preclinical research for global new drug R&D enterprises and life science research institutions.

• Small Molecules for Ferroptosis-based Cancer Therapy Platform

In our labs, we synthesize and modify specific small molecules targeting different ferroptosis signaling pathways, such as SLC7A11/ GPX4, p53, nuclear factor erythroid 2-related factor 2(NRF2)/ heme oxygenase-1 (HO-1), ferritin heavy chain 1 (FTH1) to induce anti-tumor activities in different cancer models, providing a new research idea for cancer therapy. Our ferroptosis small molecule-mediated anti-tumor technology involves more targets, fewer side effects, strong efficacy, and low cost, and is suitable for various cancer therapies. Meanwhile, these small molecules can be synergistic with traditional chemotherapy or targeted drugs, can more effectively reduce the risk of systemic toxicity improve effectiveness, and open up new avenues for cancer immuotherapy.

Fig.2 The Main Purpose of Nanomaterials to Target Ferroptosis.²

• Nanomaterials for Ferroptosis-based Cancer Therapy Platform

Creative Biolabs has established a nano-ferroptosis cancer therapy development platform based on nanoemulsion technology, nano liposome technology, nanocrystal technology, nanosuspension technology, and nanoparticle technology. Up to now, we have developed several multifunctional nano-ferroptosis inducers based on the inherent physical and chemical properties of nanomaterials. We found that these nano-ferroptosis inducers can compensate for the lack of endogenous iron and accelerate the ferroptosis process of tumor cells by improving the efficiency of the Fenton reaction.

• Gene Technologies for Ferroptosis-based Cancer Therapy Platform

In the process of studying the novel metabolic mechanism of tumor resistance to ferroptosis, we have established a gene reprogramming therapy technology platform targeting specific ferroptosis regulators. For example, we induced ferroptosis by targeting SLC47A1, a key target of lipid metabolic reprogramming, to achieve the purpose of cancer therapy. The data derived from our labs have indicated that SLC47A1 can act as a lipid metabolic checkpoint during ferroptosis, participate in the maintenance of intracellular cholesterol ester homeostasis, and regulate the ferroptosis of tumor cells.

With a strong focus on customer needs and a flexible approach to ferroptosis-based cancer therapy study design, Creative Biolabs can create customized ferroptosis solutions that exceed customer expectations, making it the ideal partner for your new oncology therapy development project. If you are interested in our services, please contact us or send us an inquiry.

References

1. Liu, Xuan, et al. "Targeting ferroptosis pathway to combat therapy resistance and metastasis of cancer." Frontiers in pharmacology 13 (2022): 909821.
2. Luo, Lianxiang, et al. "Targeting ferroptosis-based cancer therapy using nanomaterials: Strategies and applications." Theranostics 11.20 (2021): 9937.

For Research Use Only | Not For Clinical Use